HIGHLIGHTS
- who: Mailee Huynh et al. from the Editor:, University of Catanzaro have published the research: HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs, in the Journal: PLOS ONE
- what: The authors report that the proteoglycan tandem repeat 1 (PTR1) domain of the TME matrix protein hyaluronan and proteoglycan link protein 1 (HAPLN1) induces a host of cell survival genes in MM cells and variable resistance to different classes of clinical drugs including certain proteasome inhibitors steroids immunomodulatory drugs and DNA damaging agents in several MM cell lines tested. The authors report . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.